Irina V. Mikheeva

Irina V. Mikheeva

Auto-generated profile, based on publicly available information

Irina V. Mikheeva

Central Research Institute of Epidemiology of Rospotrebnadzor

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Vaccine
Verified
Journal Article
Closed access
SRSvetlana I. Rogovskaya
Svetlana I. Rogovskaya
ISIrina P. Shabalova
Irina P. Shabalova
IMIrina V. Mikheeva
Irina V. Mikheeva
GMGalina N. Minkina
Galina N. Minkina
NPNataly M. Podzolkova
Nataly M. Podzolkova
MPMario Poljak
Mario Poljak

30 December 2018 in Journal Infectology
Verified
Journal Article
Open access
PDF file
IMI. V. Mikheeva
I. V. Mikheeva
TST. S. Saltykova
T. S. Saltykova
MMM. A. Mikheeva
M. A. Mikheeva
The goal of study was the epidemiological substantiationof optimization measures of a vaccinal prevention of whooping cough in the Russian Federation. Materials and methods. The retrospective descriptive epidemiological research has been conducted by analysis of the official statistical data on the whooping cough case rate (form No. 2) in 2005–2017 in the Russian Federation, as well as the data about preventive whooping cough inoculations (forms No. 5, No. 6) in 2005–2017 and about epidemic outbreakes in 2017 (form No. 23-17). The assessment of an economic damage from whooping cough in 2005-2017 has been carried out. Results. The following adverse characteristics of a modern epidemiological situation on whooping cough in Russia are shown: long-term recurrence of epidemic process, tendency of rising of a case rate of children of 0-2 years; high percentage of children of preschool and school age among whooping cough cases; prevalence among the patients with whooping cough of the children who have been vaccinated against this infection previously, epidemic outbreakes in children’s collectives, the stability of a case rate of teenagers and adults with prevalence of the mild and the erased clinical forms of this infection. The risks due to weaknesses of the whooping cough vaccinal prevention are noted: the insufficient immunization coverage owing to falce contraindications and refusals of parents of vaccinations of children, noncompliance with terms and intervals between inoculations, lack of domestic vaccine for revaccination of children at the age of 5 years and older. Conclusion. It is necessary to introduce in the national vaccination schedule a preschool booster dose for children at the age of 6 and adolescents at 14 years with the combined reduced antigen content tetanus–diphtheria and acellular pertussis vaccines as well as the inoculations of this vaccine according to epidemiological indications to health workers, employees of educational institutions. A revaccination against whooping cough is recommended as “cocoon” for the persons contacting to not vaccinated child under 1 year of age.

6 May 2020 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
MMMarina A. Mikheeva
Marina A. Mikheeva
IMIrina V. Mikheeva
Irina V. Mikheeva
Purpose: rank-based assessment of the economic impact of infectious diseases in the Russian Federation for the further analysis of effectiveness of their prevention and for prioritization of preventive measures.Materials and Methods. The annual economic burden was eStimated by using inflation-adjusted standard economic costs of one case of infectious disease in the Russian Federation. The data on the number of cases were obtained from the official statistical reports (Forms 1, 2) for 2009-2019. The annual burden of the specific disease was estimated by multiplying the standard cost of 1 case by the number of cases registered within a given year. The economic costs were assessed and ranked.Results and discussion. In 2019, the greatest economic burden was exerted by acute respiratory infections, tuberculosis, acute gastrointestinal infections, chickenpox, HIV infection (newly diagnosed cases and deaths in 2019). The economic burden of rotavirus infection was assessed and ranked for the first time. The ranking analysis of the economic costs in 2009-2019 showed the largest decrease in the economic burden of influenza, rubella, acute and chronic hepatitis B. At the same time, the economic burden of measles, pertussis, hemorrhagic fevers and tick-borne borreliosis demonstrated an upward trend. The possibility of using ranking dynamics of economic burden as a performance indicator of epidemiological control has been demonstrated. In response to limited public funding of healthcare, the offered method can be used in setting priorities in decision making in the field of epidemic control.

30 March 2019 in Journal Infectology
Verified
Journal Article
Open access
PDF file
IMI. V. Mikheeva
I. V. Mikheeva
NFN. N. Fomkina
N. N. Fomkina
MMM. A. Mikheeva
M. A. Mikheeva
The goal of the study was the identification of epidemiological features of whooping cough and assessment of economic losses due to this disease in Moscow. Materials and methods. The retrospective descriptive epidemiological research is conducted. The statistical data on incidence of whooping cough in the Russian Federation and in Moscow from 2009 to June, 2018, the reports on registration of whooping cough cases as well as the results of laboratory testing on whooping cough in Moscow in 2017 have been studied. The general losses from whooping cough in Moscow in 2017 have been calculated. Results. The whooping cough incidence in Moscow considerably influences a situation on this infection in the country in general as more than 20% of all cases of whooping cough in Russia are registered in the capital, where the incidence exceed by 1.5–2.5 times the average country level. The incidence of whooping cough among children of 7–14 years and the share of this group of population in the structure of the whooping cough cases have increased in Moscow, and outbreaks of pertussis at schools are observed. In Moscow the general losses due to whooping cough in children of 7–14 years in 2017 were estimated as 19.72 million rubles. High performance of vaccinal prevention of whooping cough is confirmed: in Moscow in 2017 the coefficient of epidemiological efficiency of vaccination among children of 6-12 months was 97.7%, among children at the age of 1 year – 82.6%, 2 years -79.9%, 3 years – 74.9%. Weighted average of direct loss from a case of whooping cough was estimated as 31182.2 rubles. The general losses due to whooping cough in Moscow in 2017 were 67.88 million rubles. Conclusion. It is necessary to take additional measures for vaccinal prevention of whooping cough at children of school age and to support the high level of coverage by timely immunization of children of the first year of life. For assessment of economic feasibility of vaccinal prevention of whooping cough it is necessary to consider the size of economic losses due to this disease.

5 November 2021 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
NBN. I. Briko
N. I. Briko
AMA. Ya. Mindlina
A. Ya. Mindlina
IMI. V. Mikheeva
I. V. Mikheeva
LPL. D. Popovich
L. D. Popovich
ALAlyona Vyacheslavovna Lomonosova
Alyona Vyacheslavovna Lomonosova
Relevance. Currently, the national calendar of preventive vaccinations does not provide for revaccination against whooping cough in children over the age of 18 months. At the same time, the epidemiological and economic feasibility of revaccination against whooping cough in children aged 6–7 years, as well as adolescents, has been demonstrated in world practice. Aim. Based on a mathematical model, develop a forecast of pertussis morbidity dynamics and assess the potential socio-economic damage under the current and expanded vaccine prophylaxis algorithms.Methods. Mathematical modeling of the potential effect of revaccination against whooping cough in children aged 6–7 years (scenario 1) and at 6–7 years and 14 years (scenario 2) was carried out within the framework of the national calendar of preventive vaccinations. A simulation dynamic mathematical model is constructed that allows predicting the development of the epidemiological process of whooping cough on the basis of the dynamics of the main indicators of its prevalence in the population that developed in previous years. The model took into account dynamic changes in the preventive effectiveness of vaccinations and the potential level of underestimation of morbidity. The obtained arrays of indicators served as the basis for extrapolating trends in morbidity and mortality until 2034.The calculation of epidemiological benefits was carried out in the metrics of prevented loss of years of life under the two scenarios under consideration in comparison with the current vaccination algorithm. The calculation of the economic effect was carried out on the basis of the obtained indicators of epidemiological benefits in the metrics of the monetary equivalent of the average cost of a year of life, taking into account the projected inflation coefficients until 2034.Results. The projected decrease in the number of years of life lived in a state of illness, in comparison with the current situation, will total 44.5 thousand years for the period 2019–2034 under scenario 1 and 66.7 thousand years under scenario 2. The socio-economic damage from prevented cases of the disease, expressed in the monetary equivalent of the average cost of living, will decrease by 28.6% (scenario 1) or 42.0% (scenario 2).Conclusions. A comparison of the received public benefits with the costs of vaccination shows that the expansion of the NCPP with additional revaccinations against whooping cough (at 6–7 years or at 6–7 and at 14 years) is advisable both in epidemiological and economic aspects.

1 January 2017 in Pediatric pharmacology
Verified
Journal Article
Open access
PDF file
ARAlla V. Rudakova
Alla V. Rudakova
SKSusanna M. Kharit
Susanna M. Kharit
LLLyudmila V. Lyalina
Lyudmila V. Lyalina
ALAlla S. Lisianskaya
Alla S. Lisianskaya
SPSvetlana A. Protsenko
Svetlana A. Protsenko
СХС. М. Харит
С. М. Харит
Фармакоэкономические аспекты вакцинации против папилломавирусной инфекции девочек-подростков в Российской Федерации